Thanks to your incredible support, the petition is gaining traction — now just shy of 27,000 signatures. Every signature, comment, and video has amplified the message, and here’s the latest update.

The GLP-1 Collective nonprofit recently collaborated with I-MAK, a nonprofit that has been leading the fight for equity in drug access for more than a decade.

I-MAK’s 2018 report on insulin patents revealed how pharmaceutical companies filed dozens of overlapping patents to keep prices high and delay affordable alternatives. That research helped pave the way for real change, including the $35/month insulin cap for Medicare.

Now, I-MAK has turned its focus to GLP-1s. Their new report shows more than 300 patents filed across just 5 GLP-1 drugs, many of which represent only minor tweaks that don’t improve patient outcomes but extend monopolies well into the late 2030s.

The GLP-1 Collective supported this work by helping connect I-MAK with patients willing to share their stories. Because behind every data point is a real person facing barriers to care.

🎥 Watch I-MAK’s Video
📄 Read I-MAK’s Report
💻 Read our Newsletter

Together, these efforts are shining a light on access barriers and making it harder to ignore the reality patients face.

Disclaimer: This update is written in my own words and perspective. It does not represent or imply official statements or endorsements by the GLP-1 Collective. The GLP-1 Collective is a 501(c)(3) nonprofit organization. Donations are tax-deductible where allowed by law. The organization is not currently registered to solicit in all states.